The Online Investor
Biotechnology M&A image Biotechnology M&A » By The Online Investor Staff, updated Sun., Apr. 18, 3:43 AM Recent mergers and acquisitions in the Biotechnology M&A category.

Slide #72. PAREXEL International Corporation Liquent, Inc.

Acquirer: PAREXEL International Corporation (PRXL)
Acquiree: Liquent, Inc.
Details: PAREXEL International Corporation (Nasdaq: PRXL) announced today that on December 21, 2012, the Company acquired all of the outstanding equity securities of Liquent, Inc., a leading global provider of Regulatory Information Management (RIM) solutions. Liquent provides an integrated platform of software solutions for regulatory submissions and product registration management, as well as a range of complementary business process outsourcing capabilities. Liquent was founded in 1994, and its clients include more than 200 biopharmaceutical and life sciences companies. With headquarters in Horsham, Pennsylvania, and additional offices in the United Kingdom, Germany and India, the Company employs nearly 300 individuals. Prior to the sale, Liquent was owned by Marlin Equity Partners. The purchase price was approximately $72 million (which was adjusted at closing to reflect Liquent's cash, indebtedness and working capital balances at closing), and was funded through the expansion of one of the Company's existing credit facilities.

PAREXEL International is a biopharmaceutical outsourcing services company providing clinical research, clinical logistics, medical communications, consulting, commercialization and technology products and services to the pharmaceutical, biotechnology, and medical device industries. Co.'s product and service offerings include: clinical trials management, observational studies and patient/disease registries, data management, biostatistical analysis, epidemiology, health economics/outcomes research, pharmacovigilance, medical communications, clinical pharmacology, patient recruitment, clinical supply and drug logistics, post-marketing surveillance, and medical imaging services.

Open the PRXL Page at The Online Investor »

Company Name: 
PAREXEL International Corp
Stock buyback: 
PRXL buyback
Sector: 
Biotechnology
 

Open the PRXL Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes



Hold (2.00 out of 4)
100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Biotechnology M&A - Slide 72 of 83 Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2021, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.